ArticleDiscover oncology2026
Durable complete metabolic responses to androgen receptor-targeted therapy in metastatic primary cutaneous apocrine carcinoma: a case report and literature review.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrimary cutaneous apocrine carcinoma (PCAC) is an exceptionally rare adnexal malignancy with limited evidence to guide systemic treatment. Androgen receptor (AR) expression is common, but durable responses to AR-targeted therapy have been reported only in isolated cases. This case highlights a uniquely reproducible and profound complete metabolic response to AR blockade in metastatic PCAC, offering valuable insight into its potential hormonal dependence. CASE PRESENTATION: A 57-year-old man with AR-strong PCAC of the axilla developed metastatic relapse involving mediastinal and axillary lymph nodes, lung lymphangitic spread, and a lytic vertebral lesion. Treatment with enzalutamide combined with goserelin resulted in a rapid and complete metabolic response on PET-CT. After therapy interruption due to cumulative fatigue and vasomotor symptoms, mild nodal progression and a new cutaneous recurrence occurred. Re-induction with the same regimen again resulted in complete metabolic and radiologic remission, which remained durable on follow-up.
conclusionThis case demonstrates that AR-targeted therapy may induce deep, durable, and reproducible metabolic responses in AR-positive metastatic PCAC, even after treatment re-challenge. Comprehensive molecular and immunohistochemical profiling is essential for identifying actionable pathways in this rare tumour. The findings contribute meaningful evidence to the limited literature and may support further investigation of AR signalling as a therapeutic target in PCAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.